Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)

Clinical trial NCT06036836 · COMPLETED

Trial details

NCT number: NCT06036836
Sponsor: Merck Sharp & Dohme LLC
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Solid Tumor Cutaneous Squamous Cell Carcinoma Endometrial Cancer

Start date: 2023-09-29
Primary completion: 2026-03-12
Enrollment: 163

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.